5062352026-01-012026-03-315062352026-03-315062352025-03-315062352025-04-012026-03-315062352026-01-012026-03-31in-capmkt:OtherExpenses1Member5062352026-01-012026-03-31in-capmkt:OtherExpenses2Member5062352025-04-012026-03-31in-capmkt:OtherExpenses1Member5062352025-04-012026-03-31in-capmkt:OtherExpenses2Member5062352026-03-31OtherNoncurrentFinancialAssetsDomain15062352026-03-31OtherNoncurrentAssetsDomain15062352026-03-31OtherCurrentFinancialAssetsDomain15062352026-03-31OtherCurrentAssetsDomain15062352026-03-31OtherNoncurrentFinancialLiabilitiesDomain15062352026-03-31OtherCurrentFinancialLiabilitiesDomain15062352026-03-31OtherCurrentLiabilitiesDomain15062352026-01-012026-03-31in-capmkt:ReportableSegments1Member5062352026-01-012026-03-31in-capmkt:ReportableSegments2Member5062352025-04-012026-03-31in-capmkt:ReportableSegments1Member5062352025-04-012026-03-31in-capmkt:ReportableSegments2Member5062352026-01-012026-03-31in-capmkt:ReportableSegments1Member5062352026-01-012026-03-31in-capmkt:ReportableSegments2Member5062352025-04-012026-03-31in-capmkt:ReportableSegments1Member5062352025-04-012026-03-31in-capmkt:ReportableSegments2Member5062352026-01-012026-03-31in-capmkt:ReportableSegments1Member5062352026-03-31in-capmkt:ReportableSegments1Member5062352026-01-012026-03-31in-capmkt:ReportableSegments2Member5062352026-03-31in-capmkt:ReportableSegments2Member5062352026-01-012026-03-31in-capmkt:ReportableSegments1Member5062352026-03-31in-capmkt:ReportableSegments1Member5062352026-01-012026-03-31in-capmkt:ReportableSegments2Member5062352026-03-31in-capmkt:ReportableSegments2Member5062352026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares506235ALEMBICLTDNOTLISTEDINE426A01027Alembic LimitedMain BoardEquity2025-04-012026-03-312026-05-192026-05-08INRLakhsQuarterlyFourth quarterMulti segment2026-05-1916:30:002026-05-1917:45:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated60042000021424000621844000404070000-64560001174320005681000334440002469200004374280001844160000184416000565770003173800088315000096101000000575151000671252000-1009904000-338652000-3386510000-1009904000051356400022.612.61002.612.611. The above results have been audited by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. <BR> <BR> 2. The Board has recommended Dividend on equity shares at Rs 2.40 per share (face value Rs. 2/- each) i.e 120% for the year ended on 31st March, 2026 (Previous year Rs. 2.40 per share i.e 120%.) <BR> <BR> 3. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year. <BR> <BR> 4. The figures for the quarter ended 31st March, 2026 and corresponding quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year and year to date figures upto third quarter of the respective financial years which were subject to limited review. <BR> <BR> 5. The Government of India has notified the implementation of four new Labour Codes effective 21st November, 2025, by consolidating and rationalizing 29 existing labour laws. The Company has provisionally estimated the financial implications thereof and has made additional provision under 'Employee Benefit Expense' for Rs. 143.72 lakh in the financial results for the quarter ended on 31st December, 2025. This will be reviewed and revised, if required once all applicable Rules are notified by the Government on all aspects of the Codes. <BR> <BR> 6. Figures rounded off to the nearest decimal.2025-04-012026-03-31AuditedConsolidated2399898000729655000312955300013875400002551200037444900022784000123882000956585000164196600014875870000148758700022625000020140002282640000125932300000019144670003173790000-875493000229829700022982970000-875493000051356400022249265500012.3612.360012.3612.36Cost of Construction146350000Other Expenses100570000Cost of Construction600174000Other Expenses3564110001699522000150210003017136000507000000170442620001730975000006523200017962070000350000000239226550005224110009662430003190290001411800018733000035304000135342700009658700019724250000025895080000513564000239372920002445085600024450856000661080000001350390002011470003715300019288700004311870004027700068665000169774000238439000116838000395554000300989000228005000884890000101303700000144422400025895080000Other non-current financial assets65232000Other non-current assets350000000Other current financial assets35304000Other current assets96587000Other non-current financial liabilities135039000Other current financial liabilities116838000Other current liabilities300989000Active Pharmaceutical Ingredients Business98312000Real Estate Business502108000Active Pharmaceutical Ingredients Business465852000Real Estate Business193404600060042000023998980006004200002399898000Active Pharmaceutical Ingredients Business-11708000Real Estate Business209742000Active Pharmaceutical Ingredients Business56495000Real Estate Business8116850001980340008681800005681000227840007936000-6421910001844170001487587000Active Pharmaceutical Ingredients Business1808125000Real Estate Business515780600069659310001892915000025895081000Active Pharmaceutical Ingredients Business348044000Real Estate Business8148040001162848000281376000144422400022784000471459000-19332000031993000027116000-34400000-441700000-13624400001238820000158790001274000035813000103810000629517000156200000309600000000-931800001394407000000193756000012006510000012978420001712941000000003824540000384058000000000000000000629517000156200000-2146000-5386200000000000003808900006141430002278400000-675016000-129850000-1298500027103000141180001048289000963679000-38385000-88186000-1009904000-875493000AuditedtrueCNK & ASSOCIATES LLPtrue2026-07-31